SCHEMBL21114779

SCHEMBL21114779

N#Cc1ccc(S(=O)(=O)Nc2ccc([As]=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.61
CYP19A1 P11511 2/20 0.59
AR P10275 1/20 0.54
BRD4 O60885 3/20 0.52
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
TP53 P04637 1/20 0.51
THRB P10828 1/20 0.51
IDO1 P14902 1/20 0.50
ATIC P31939 2/20 0.49
HSPD1 P10809 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN5 P54829 1/20 0.49
HSPE1 P61604 1/20 0.49
CACNA1H O95180 1/20 0.49
CACNA1B Q00975 1/20 0.49
BRD1 O95696 4/20 0.48
BRPF1 P55201 4/20 0.48
BRPF3 Q9ULD4 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7281538 0.81 KDM1A (0.68) KDM1ACYP19A1ARBRD4CA1
SCHEMBL6555449 0.81 KDM1A (0.68) KDM1ACYP19A1ARBRD4CA1
SCHEMBL7572500 0.81 CES1 (0.73) KDM1ACYP19A1ARBRD4CA1
SCHEMBL6554559 0.81 CES1 (0.73) KDM1ACYP19A1ARBRD4CA1
SCHEMBL96241 0.81 KDM1A (0.64) KDM1ACYP19A1ARBRD4CA1
SCHEMBL27888183 0.81 CA1 (0.65) KDM1ACYP19A1ARBRD4CA1
SCHEMBL14645822 0.80 CYP19A1 (0.75) KDM1ACYP19A1ARCA1CA2
SCHEMBL7572258 0.80 CYP19A1 (0.75) KDM1ACYP19A1ARCA1CA2
SCHEMBL21114799 0.79 CA12 (0.64) CA1CA2TP53MAPT
SCHEMBL21114782 0.79 NPSR1 (0.54) ARIDO1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173287-A1 Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2024-05-30 US disclosed
US-11766420-B2 Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) 2023-09-26 US disclosed
US-11236378-B2 Method for screening drug and therapeutic targets used for treating Alzheimer's disease Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) 2022-02-01 US disclosed
US-20190314321-A1 Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2019-10-17 US disclosed
US-20190211371-A1 Method For Screening Drug And Therapeutic Targets Used For Treating Alzheimer's Disease JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314321-A1 Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease PI4K2A, PI4K2B, PIP4K2A KDM1A 4151/4885CYP19A1 3403/4885AR 2393/4885
US-11236378-B2 Method for screening drug and therapeutic targets used for treating Alzheimer's disease PSD, TBRG4, ACTR3 KDM1A 4501/4885CYP19A1 3510/4885AR 3111/4885
US-11766420-B2 Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease PI4K2A, PI4K2B, PIP4K2A KDM1A 4151/4885CYP19A1 3403/4885AR 2393/4885
US-20240173287-A1 Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease PI4K2A, PI4K2B, PIP4K2A KDM1A 4151/4885CYP19A1 3403/4885AR 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.